HSTO

Histogen Appoints Rochelle Fuhrmann to Board of Directors

Histogen and Amerimmune Announce First Patient Dosed in Phase 1 Study of Emricasan in Symptomatic COVID-19 Patients

HSTO Stock Price Increases Over 5% Pre-Market: Why It Happened

Histogen Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Update

Histogen Strengthens Board of Directors with Appointment of Industry Leader Susan Windham-Bannister, Ph.D.

Histogen to Report Fourth Quarter and Year-End 2020 Financial Results and Provide Business Update

Histogen Reports FDA Clinical Hold for Planned Phase 1/2 Trial of HST-003 for Knee Cartilage Regeneration